Enhanced safety and immunogenicity of a pneumococcal surface antigen A mutant whole-cell inactivated pneumococcal vaccine
© 2019 Australian and New Zealand Society for Immunology Inc..
Existing capsular polysaccharide-based vaccines against pneumococcal disease are highly effective against vaccine-included serotypes, but they are unable to combat serotype replacement. We have developed a novel pneumococcal vaccine that confers serotype-independent protection, and could therefore constitute a "universal" vaccine formulation. This preparation is comprised of whole un-encapsulated pneumococci inactivated with gamma irradiation (γ-PN), and we have previously reported induction of cross-reactive immunity after nonadjuvanted intranasal vaccination. To further enhance vaccine immunogenicity and safety, we modified the pneumococcal vaccine strain to induce a stressed state during growth. Specifically, the substrate binding component of the psaBCA operon for manganese import was mutated to create a pneumococcal surface antigen A (psaA) defective vaccine strain. psaA mutation severely attenuated the growth of the vaccine strain in vitro without negatively affecting pneumococcal morphology, thereby enhancing vaccine safety. In addition, antibodies raised against vaccine preparations based on the modified strain [γ-PN(ΔPsaA)] showed more diversified reactivity to wild-type pneumococcal challenge strains compared to those induced by the original formulation. The modified vaccine also induced comparable protective TH 17 responses in the lung, and conferred greater protection against lethal heterologous pneumococcal challenge. Overall, the current study demonstrates successful refinement of a serotype-independent pneumococcal vaccine candidate to enhance safety and immunogenicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
Immunology and cell biology - 97(2019), 8 vom: 05. Sept., Seite 726-739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
David, Shannon C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.05.2020 Date Revised 05.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/imcb.12257 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296695920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296695920 | ||
| 003 | DE-627 | ||
| 005 | 20231225090406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imcb.12257 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0988.xml |
| 035 | |a (DE-627)NLM296695920 | ||
| 035 | |a (NLM)31050022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a David, Shannon C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced safety and immunogenicity of a pneumococcal surface antigen A mutant whole-cell inactivated pneumococcal vaccine |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2020 | ||
| 500 | |a Date Revised 05.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Australian and New Zealand Society for Immunology Inc. | ||
| 520 | |a Existing capsular polysaccharide-based vaccines against pneumococcal disease are highly effective against vaccine-included serotypes, but they are unable to combat serotype replacement. We have developed a novel pneumococcal vaccine that confers serotype-independent protection, and could therefore constitute a "universal" vaccine formulation. This preparation is comprised of whole un-encapsulated pneumococci inactivated with gamma irradiation (γ-PN), and we have previously reported induction of cross-reactive immunity after nonadjuvanted intranasal vaccination. To further enhance vaccine immunogenicity and safety, we modified the pneumococcal vaccine strain to induce a stressed state during growth. Specifically, the substrate binding component of the psaBCA operon for manganese import was mutated to create a pneumococcal surface antigen A (psaA) defective vaccine strain. psaA mutation severely attenuated the growth of the vaccine strain in vitro without negatively affecting pneumococcal morphology, thereby enhancing vaccine safety. In addition, antibodies raised against vaccine preparations based on the modified strain [γ-PN(ΔPsaA)] showed more diversified reactivity to wild-type pneumococcal challenge strains compared to those induced by the original formulation. The modified vaccine also induced comparable protective TH 17 responses in the lung, and conferred greater protection against lethal heterologous pneumococcal challenge. Overall, the current study demonstrates successful refinement of a serotype-independent pneumococcal vaccine candidate to enhance safety and immunogenicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a gamma-irradiation | |
| 650 | 4 | |a mucosal immunity | |
| 650 | 4 | |a pneumococcal vaccine | |
| 650 | 4 | |a serotype-independent | |
| 650 | 7 | |a Adhesins, Bacterial |2 NLM | |
| 650 | 7 | |a Antigens, Surface |2 NLM | |
| 650 | 7 | |a Lipoproteins |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 650 | 7 | |a PsaA protein, Streptococcus |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 700 | 1 | |a Laan, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Minhas, Vikrant |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Austen Y |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Hirst, Timothy R |e verfasserin |4 aut | |
| 700 | 1 | |a McColl, Shaun R |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharifi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Paton, James C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology and cell biology |d 1992 |g 97(2019), 8 vom: 05. Sept., Seite 726-739 |w (DE-627)NLM012699896 |x 1440-1711 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2019 |g number:8 |g day:05 |g month:09 |g pages:726-739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imcb.12257 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2019 |e 8 |b 05 |c 09 |h 726-739 | ||